biote Corp.

biote Corp.

BTMDNYSE / NASDAQHealthcareSmall cap

$0.81-$0.03 (-3.6%)

Last close · Data as of Nov 20, 2026

Market cap
$83.9M
P/E
3.1x
EV / EBITDA
3.3x
Revenue
$192.2M
Net margin
14.1%
ROCE
56.8%

-66.0% over the last year

biote Corp. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-23.8%
3M
-44.9%
6M
-61.2%
1Y
-66.0%
5Y
-91.6%

52-week range

Day change -$0.03 (-3.6%) from $0.85 to $0.81 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BTMD, bought on each weekday since 2021.

News & filings

What biote filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Return on capital employed of 56.8%.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.

Read moreShow less

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.

Sector
Healthcare
Shares outstanding
30.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$83.9M
P/E
3.1x
P/B
-1.4x
EV / EBITDA
3.3x
EV / Sales
0.9x
P/S
0.4x
52-week high
$2.85
52-week low
$0.81

Profitability

Operating margin
18.5%
Net margin
14.1%
EBITDA margin
27.2%
ROE
-46.2%
ROCE
56.8%
ROIC
115.3%
ROA
25.1%
Asset turnover
1.79

Growth

Revenue
$192.2M
Revenue growth, 1Y
-2.5%
Revenue CAGR, 3Y
5.2%
Net profit growth, 1Y
756.7%
Free cash flow
$28.3M

Solvency

Current ratio
1.22
Debt / Equity
-1.88
Debt / Assets
1.02
CFO / Net profit
1.30
Cash / Market cap
28.8%

Where the revenue went

Of every $100 of FY2025 revenue, $14 was left as net income.

biote Corp. income statement flow, FY2025
biote Corp. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$54.9M
RevenueGross profit$137.4M
Gross profitSelling, general and administrative$101.8M
Gross profitOther operating expenses$0.00
Gross profitOperating income$35.5M
Operating incomePretax income$35.5M
Interest and other incomePretax income$2.0M
Pretax incomeTax and other$10.5M
Pretax incomeNet income$27.0M

Revenue and net profit

Revenue fell 2.5% in FY2025; net profit is the dashed line.

biote Corp. revenue and net profit by fiscal year
biote Corp. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$165.0M-$969.0k
FY2023$185.4M$3.3M
FY2024$197.2M$3.2M
FY2025$192.2M$27.0M

Cash flows

FY2025: $35.2M from operations, $28.3M free after investment (dashed).

biote Corp. operating and free cash flow by fiscal year
biote Corp. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$9.2M-$11.0M
FY2023$26.9M$24.2M
FY2024$45.2M$38.3M
FY2025$35.2M$28.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$192.2M-2.5%1Y
EBITDA
$52.2M+234.9%1Y
Net profit
$27.0M+756.7%1Y
Cash from operations
$35.2M-22.2%1Y
Free cash flow
$28.3M-26.0%1Y
Revenue CAGR, 3Y
5.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$192.2M$52.2M$27.0M$28.3M-46.2%-2.5%+756.7%

Monthly returns

Month-by-month returns of BTMD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$107.6M
Liabilities$158.0M
Equity-$50.4M
Paid-in capital$0.00
Retained earnings-$49.5M
Treasury stock$9.0M
Minority interest$8.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BTMD highlighted.

P/E against peers

BTMD trades at 3.1x earnings against a peer median of -1.3x.

  1. biote Corp. (this company)3.1x

Not shown (no positive earnings and no EV / Sales): Aardvark Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
biote Corp.BTMDthis company$83.9M3.1x-1.4x-46.2%3.3x
Neuronetics, Inc.STIM$101.6M-2.6x4.5x-174.3%-5.8x
OptimizeRx CorporationOPRX$101.0M19.7x0.8x4.0%6.3x
Definitive Healthcare Corp.DH$95.7M-0.7x0.3x-49.4%-0.7x
Heron Therapeutics, Inc.HRTX$91.5M—6.4x-141.0%—
Outset Medical, Inc.OM$87.7M-1.1x0.7x-64.3%-2.5x
Aardvark Therapeutics, Inc.AARD$86.0M-1.5x0.8x-54.0%-0.6x
Pulmonx CorporationLUNG$68.4M—1.3x-99.8%—
LENSAR, Inc.LNSR$68.0M-2.0x-2.6x131.7%-2.9x
Peer median—-1.3x0.8x-59.2%-1.6x

Year-to-date ROI

BTMD since 1 January, against earlier years.

Historical volatility

BTMD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

biote Corp. operating margin by fiscal year
biote Corp. operating margin by fiscal year
DateOperating margin
FY2022-36.8%
FY202315.5%
FY202416.0%
FY202518.5%
LineFY2025
Cost of revenueCost Of Revenue$54.9M
Gross profitGross Profit$137.4M
Operating expensesOperating Expense$101.8M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$156.7M
Pretax incomePretax Income$37.6M

Learn while you research

Academy chapters picked for biote Corp. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 3.1 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →